CDK14

Cyclin-dependent kinase 14

15,117 patent compounds predicted against CDK14, 12,227 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
At-7519 (SCHEMBL1069453)	0.59	13/20
At-7519 (SCHEMBL955568)	0.64	10/20
At-7519 (SCHEMBL953647)	0.62	10/20
SCHEMBL954955	0.51	9/20
SCHEMBL954966	0.55	8/20
SCHEMBL959301	0.54	8/20
SCHEMBL957511	0.54	8/20
SCHEMBL1070972	0.52	8/20
SCHEMBL956928	0.47	4/20
SCHEMBL956930	0.48	3/20
SCHEMBL959133	0.43	3/20
SCHEMBL147331	0.91	2/20
SCHEMBL141930	0.90	2/20
SCHEMBL142206	0.85	2/20
SCHEMBL144842	0.80	2/20
SCHEMBL144192	0.75	2/20
SCHEMBL144525	0.71	2/20
SCHEMBL146263	0.71	2/20
SCHEMBL141676	0.69	2/20
SCHEMBL145500	0.69	2/20

Germline variants in CDK14 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CDK14 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CDK14 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer	PHASE3	ACTIVE_NOT_RECRUITING
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)	PHASE3	COMPLETED
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients	PHASE3	RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer	PHASE2	COMPLETED
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.	PHASE2	COMPLETED
To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy	PHASE2	COMPLETED
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer	PHASE1/PHASE2	RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO	PHASE2	COMPLETED
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL	PHASE2	COMPLETED
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors	PHASE1/PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study	nan	ACTIVE_NOT_RECRUITING
Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy	nan	COMPLETED
Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer	nan	UNKNOWN
The SONImage Study	nan	ACTIVE_NOT_RECRUITING
Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer	nan	COMPLETED
Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor	nan	UNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CDK14 binder may also engage these)

Protein	Name	Similarity
C0RW22	—	1.000	C0RW22 →
O35495	—	1.000	O35495 →
B0VXL7	—	1.000	B0VXL7 →
Q6DJM7	—	1.000	Q6DJM7 →
A4IIW7	—	1.000	A4IIW7 →
B0VXE8	—	1.000	B0VXE8 →
B6A7Q3	—	1.000	B6A7Q3 →
O35832	—	0.998	O35832 →
O35831	—	0.998	O35831 →
Q8VZD5	—	0.996	Q8VZD5 →
P51138	—	0.996	P51138 →
Q04899	—	0.996	Q04899 →
Q8K0D0	—	0.995	Q8K0D0 →
Q63686	—	0.995	Q63686 →
CDK17	Cyclin-dependent kinase 17	0.994	landscape →
CDK16	Cyclin-dependent kinase 16	0.994	landscape →
Q9C9U2	—	0.994	Q9C9U2 →
G5EBT1	—	0.993	G5EBT1 →
Q4WYR6	—	0.993	Q4WYR6 →
CDK18	Cyclin-dependent kinase 18	0.993	landscape →
Q1RLU9	—	0.993	Q1RLU9 →
Q9U2Q9	—	0.993	Q9U2Q9 →
P43289	—	0.992	P43289 →
Q5RD01	—	0.992	Q5RD01 →
Q5BAE1	—	0.992	Q5BAE1 →
Q4FCZ5	—	0.992	Q4FCZ5 →
Q04735	—	0.992	Q04735 →
DCLK1	Serine/threonine-protein kinase DCLK1	0.991	landscape →
O23145	—	0.991	O23145 →
Q40518	—	0.991	Q40518 →